What are the key applications of EpCAM antibodies in tumor diagnosis and treatment?

1. What is the molecular structure and functional characteristics of EpCAM protein?

Epithelial cell adhesion molecule (EpCAM, also known as CD326) is a unique type I transmembrane glycoprotein whose molecular structure does not belong to the classical classifications of cell adhesion molecules such as integrins, selectins, cadherins, or the immunoglobulin superfamily. The EpCAM protein consists of 314 amino acids and comprises three main functional domains: a large extracellular domain (242 amino acids), a single transmembrane domain (23 amino acids), and a short intracellular domain (26 amino acids). The extracellular domain contains two characteristic regions: an epidermal growth factor-like domain and a thyroglobulin-like repeat sequence, which provide the molecular basis for EpCAM-mediated homotypic cell adhesion. In terms of post-translational modifications, EpCAM has three potential N-glycosylation sites, and its molecular weight varies between 33-40 kDa depending on the degree of glycosylation. EpCAM exists as multimers on the cell surface and participates in the regulation of cell-cell interactions by forming tetrameric structures.

2. How do the coding features of the EpCAM gene influence its functional expression?

EpCAM is encoded by the TACSTD1 gene (also known as the GA733-2 gene) located on chromosome 4. This gene exhibits highly conserved evolutionary characteristics, with an open reading frame of 942 base pairs and nine exons. The functional allocation of exons is clear: exon 1 encodes the signal peptide sequence, exons 2-6 encode the extracellular domain (with exon 2 encoding the epidermal growth factor-like domain and exon 3 encoding the thyroglobulin-like repeat domain), exon 7 encodes the transmembrane region, and exons 8-9 together constitute the intracellular domain. The promoter region of this gene lacks typical TATA and CAAT boxes but contains binding sites for transcription factors such as SP1 and AP-1, which affect its transcriptional regulation. Notably, no splice variants of EpCAM mRNA have been discovered, providing a relatively stable molecular basis for antibody development based on its protein structure.

3. What is the application value of EpCAM antibodies in tumor detection?

Due to the high expression of EpCAM in various epithelial-derived tumors and its limited expression in normal epithelial tissues, its specific antibodies have become important tools for tumor diagnosis and monitoring:

1. Histopathological detection: Using immunohistochemistry, EpCAM antibodies can identify epithelial-derived malignant tumors, aiding in tumor histopathological classification and grading.

2. Circulating tumor cell (CTC) detection: EpCAM antibody-based capture systems can isolate and identify circulating tumor cells from peripheral blood, providing critical information for early diagnosis, staging, and recurrence monitoring of tumors.

3. Minimal residual disease monitoring: High-sensitivity EpCAM detection methods can assess the presence of minimal residual disease after treatment, guiding clinical decision-making.

4. Tumor marker detection: The soluble form of EpCAM protein can serve as a serum tumor marker for the auxiliary diagnosis and efficacy monitoring of specific tumors.

4. What are the mechanisms of action of EpCAM antibodies in tumor-targeted therapy?

EpCAM-targeting antibody drugs exert anti-tumor effects through multiple mechanisms:

1. Direct cytotoxic effects: Some EpCAM antibodies can directly kill tumor cells through complement-dependent cytotoxicity or antibody-dependent cell-mediated cytotoxicity.

2. Signal pathway interference: Certain EpCAM antibodies can interfere with EpCAM-mediated downstream signaling, affecting tumor cell proliferation, migration, and invasion.

3. Immunomodulatory functions: By blocking EpCAM's immunomodulatory functions, these antibodies enhance the anti-tumor activity of immune cells in the tumor microenvironment.

4. Drug-targeted delivery: Conjugating EpCAM antibodies with cytotoxic drugs to form antibody-drug conjugates enables tumor-specific drug delivery, improving the therapeutic window.

5. Cell therapy targeting: In CAR-T cell therapy, EpCAM can serve as a target antigen, guiding engineered T cells to specifically recognize and eliminate EpCAM-positive tumor cells.

5. What technical challenges are faced in the development of EpCAM antibodies?

Although EpCAM antibodies demonstrate significant value in clinical applications, their development and optimization still face multiple challenges:

1. Tissue expression heterogeneity: The expression levels of EpCAM vary significantly among different tumor types and individuals, affecting the diagnostic sensitivity and therapeutic efficacy of antibodies.

2. Complexity of molecular modifications: The glycosylation patterns of EpCAM may change under different physiological and pathological conditions, requiring higher specificity in antibody recognition.

3. Impact of the tumor microenvironment: Protease activity in the tumor microenvironment may cleave the extracellular domain of EpCAM, producing soluble fragments that affect antibody binding efficiency.

4. Immune evasion mechanisms: Tumor cells may downregulate EpCAM expression or alter its conformation to evade antibody-mediated immune recognition.

5. Toxicity risk control: Since EpCAM is also expressed in certain normal epithelial tissues, antibody therapy may carry the potential risk of targeting non-tumor tissues.

6. What is the significance of EpCAM antibody research for precision medicine?

Advances in EpCAM antibody technology have driven progress in precision tumor diagnosis and treatment. In diagnostics, EpCAM antibodies improve the sensitivity and specificity of detecting epithelial-derived tumors. In therapeutics, EpCAM-based targeting strategies provide more precise treatment options for tumor patients. With further elucidation of EpCAM signaling pathways and biological functions, as well as continuous innovation in antibody technology, EpCAM antibodies are expected to play an increasingly important role in tumor immunotherapy, cell therapy, and precision diagnostics. Future efforts should strengthen the connection between basic research and clinical translation, optimize antibody design and application strategies, and ultimately achieve individualized precision medicine based on the EpCAM target.

7. Which manufacturers provide EpCAM antibodies?

Hangzhou Start Biotech Co., Ltd. has independently developed the "S-RMab® EpCAM Recombinant Rabbit Monoclonal Antibody (S-RMab® EpCAM Recombinant Rabbit mAb (SDT-078-13))" (Catalog No.: S0B2028), a high-specificity, high-affinity, and highly consistent epithelial cell marker detection antibody. This product is developed using the company's patented S-RMab® recombinant rabbit monoclonal antibody platform technology and can specifically recognize human epithelial cell adhesion molecule (EpCAM, also known as CD326). It performs excellently in applications such as immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry (FACS), making it a key tool in epithelial-derived tumor identification, circulating tumor cell (CTC) detection, and stem cell research.

Professional technical support: We provide detailed validation data packages for this antibody, including IHC staining profiles in various normal and cancerous tissues (e.g., colon, breast, lung, pancreas), flow cytometry protocols, and recommended multicolor pairing suggestions. Our technical team offers professional application consultation.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-performance, high-value antibody tools for tumor research, translational medicine, and in vitro diagnostics. For more information about the "S-RMab® EpCAM Recombinant Rabbit Monoclonal Antibody" (Catalog No. S0B2028), to obtain validation data, or to request sample testing, please feel free to contact us.

Product Information